TY - JOUR
T1 - Addressing the Individualized Needs in Hereditary Angioedema
T2 - Managed Care Strategies to Optimize Access to Care
AU - Malesker, Mark
N1 - Funding Information:
Patients must be able to access prophylactic and on-demand treatments for HAE to meet therapy goals, reducing morbidities and preventin.3gN mumoretarolituys patient-and treatment-specific factors influence the treatment selection process, which should be accounted for by payers developing coverage criteria.49Patients requiring additional financial support may be eligible for patient assistance programs sponsored by pharmaceutical companies.
Publisher Copyright:
© 2022 Ascend Media. All rights reserved.
PY - 2022/1
Y1 - 2022/1
N2 - Hereditary angioedema (HAE) is a serious, potentially fatal disease of recurrent swelling of various subcutaneous and submucosal tissues throughout the body. Swelling is mediated by uncontrolled regulation of bradykinin, making it pathologically distinct from other forms of angioedema. Diagnosis can be challenging, but distinctions in clinical presentation and laboratory studies can confirm clinical suspicion. Though the disease is rare, the socioeconomic burden of living with and treating HAE is significant for patients and healthcare systems. As a result, there has been a dramatic expansion of treatment options specifically designed for HAE in recent years. Novel treatments are effective in treating swelling attacks, preventing recurrence, and improving patient quality of life. However, significant differences in the risks, benefits, and cost of treatments must be weighed in the determination of clinical protocols to determine optimal utilization of healthcare resources.
AB - Hereditary angioedema (HAE) is a serious, potentially fatal disease of recurrent swelling of various subcutaneous and submucosal tissues throughout the body. Swelling is mediated by uncontrolled regulation of bradykinin, making it pathologically distinct from other forms of angioedema. Diagnosis can be challenging, but distinctions in clinical presentation and laboratory studies can confirm clinical suspicion. Though the disease is rare, the socioeconomic burden of living with and treating HAE is significant for patients and healthcare systems. As a result, there has been a dramatic expansion of treatment options specifically designed for HAE in recent years. Novel treatments are effective in treating swelling attacks, preventing recurrence, and improving patient quality of life. However, significant differences in the risks, benefits, and cost of treatments must be weighed in the determination of clinical protocols to determine optimal utilization of healthcare resources.
UR - http://www.scopus.com/inward/record.url?scp=85123659512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123659512&partnerID=8YFLogxK
U2 - 10.37765/ajmc.2022.88822
DO - 10.37765/ajmc.2022.88822
M3 - Article
C2 - 35041357
AN - SCOPUS:85123659512
VL - 28
SP - S3-S9
JO - American Journal of Managed Care
JF - American Journal of Managed Care
SN - 1088-0224
ER -